Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Med Sci Monit ; 25: 10045-10056, 2019 Dec 27.
Artículo en Inglés | MEDLINE | ID: mdl-31881016

RESUMEN

BACKGROUND Barbaloin is one of the main medicinal ingredients of aloe vera, which displays various anti-inflammatory and anti-apoptosis properties in several inflammatory and fibrotic diseases. Our study evaluated its efficacy against dextran sulfate sodium (DSS)-induced colitis in rats. MATERIAL AND METHODS Ulcerative colitis (UC) rat models were established in vivo, and after barbaloin treatment, body weight and inflammation index were measured. Additionally, the signaling mechanism by which barbaloin protects against UC was investigated using LPS-infected Caco-2 cells. RESULTS Barbaloin could significantly reverse UC-induced weight loss and colon injury. Further, it could effectively increase the mRNA expression of IL-4 and IL-10 in colon tissues, while decreasing the expression of IFN-γ, IL-6, IL-1ß, and TNF-alpha. Furthermore, it significantly enhanced UC-inhibited atresia band 1 (ZO-1), occludin, and E-cadherin, and was also found to activate the AMPK signaling pathway. Additionally, si-RAN-induced knockdown, and overexpression assay showed that barbaloin could inhibit the UC-enhanced MLCK signaling pathway by activating the AMPK signaling pathway. CONCLUSIONS Barbaloin can effectively inhibit inflammation and reverse epithelial barrier function to protect against UC, possibly via activation of the AMPK signaling pathway.


Asunto(s)
Proteínas Quinasas Activadas por AMP/metabolismo , Antracenos/uso terapéutico , Colitis/tratamiento farmacológico , Colitis/enzimología , Inflamación/patología , Mucosa Intestinal/patología , Transducción de Señal , Animales , Antracenos/química , Antracenos/farmacología , Células CACO-2 , Cadherinas/metabolismo , Colitis/patología , Colitis/fisiopatología , Sulfato de Dextran , Dextranos/sangre , Modelos Animales de Enfermedad , Fluoresceína-5-Isotiocianato/análogos & derivados , Humanos , Mediadores de Inflamación/metabolismo , Mucosa Intestinal/efectos de los fármacos , Lipopolisacáridos , Masculino , Quinasa de Cadena Ligera de Miosina/metabolismo , Ocludina/metabolismo , Tamaño de los Órganos/efectos de los fármacos , Ratas Wistar , Transducción de Señal/efectos de los fármacos , Proteína de la Zonula Occludens-1/metabolismo
2.
Poult Sci ; 94(9): 2075-80, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26195804

RESUMEN

We have previously shown that intestinal barrier function can be adversely affected by poorly digested diets or feed restriction, resulting in increased intestinal inflammation-associated permeability. Three experiments were conducted in broilers to evaluate the effect of dexamethasone (DEX) treatment on systemic fluorescein isothiocyanate-dextran (FITC-D; 3-5 kDa) levels, indicative of increased gut epithelial leakage. Experiment 1 compared DEX injections of 1 mg/kg, once per day on d 3, 5, and 9, with feed administration at 0.57, 1.7, or 5.1 ppm d 4 to 10, with FITC-D serum concentrations 2.5 h after gavage with 4.16 mg/kg FITC-D. All DEX treatments resulted in marked (2 to 6X; P<0.05) increased serum FITC-D levels. Feed DEX administration resulted in greater (P<0.05) gut permeability than injection at any dose, with numerically optimal effects at the lowest dose tested. In experiments 2 and 3, chicks were randomly assigned to a starter ration containing either control (CON) or DEX treated feed (0.57 ppm/kg; d 3 to 10 experiment 2, d 4 to 10 experiment 3). At d 10, all chicks were treated by oral gavage with FITC-D and serum samples were obtained as described above. Samples of the liver were aseptically collected, homogenized, diluted 1:4 wt/vol in sterile saline, and serial dilutions were plated on tryptic soy agar to evaluate total numbers of aerobic bacteria in the liver as an index of bacterial translocation (BT). In both experiments, FITC-D absorption was significantly enhanced (P<0.05) in DEX-treated chicks, again indicating increased paracellular leakage across the gut epithelium associated with dissolution of tight junctions. Experiment 2 differential cell counts showed an increased heterophil/lymphocyte ratio, and immune organ (spleen and bursa of Fabricius) weights for experiments 2 and 3 were decreased (P<0.05) from controls. In experiments 2 and 3, dietary DEX administration resulted in numerically (experiment 2) or significantly (P<0.05) increased enteric BT to the liver, supporting the observation that dietary DEX causes a stress-like inflammatory GI response, which may contribute to subclinical or clinical disease, and may be a useful model for ongoing disease mitigation research related to stress-related diseases of GIT origin.


Asunto(s)
Antiinflamatorios/metabolismo , Pollos , Dexametasona/metabolismo , Dextranos/sangre , Fluoresceína-5-Isotiocianato/análogos & derivados , Inflamación/veterinaria , Intestinos/efectos de los fármacos , Enfermedades de las Aves de Corral/inducido químicamente , Alimentación Animal/análisis , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/farmacología , Dexametasona/administración & dosificación , Dexametasona/farmacología , Dieta/veterinaria , Suplementos Dietéticos/análisis , Relación Dosis-Respuesta a Droga , Inflamación/inducido químicamente , Intestinos/química , Recuento de Leucocitos/veterinaria , Permeabilidad/efectos de los fármacos , Distribución Aleatoria , Estrés Fisiológico
3.
Rev Med Chir Soc Med Nat Iasi ; 101(3-4): 174-7, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-10756793

RESUMEN

The paper presents the influence of the ranitidine-dextran conjugate on the gastric secretion stimulated with carbachol on rats with a ligated pylorus [correction of ligaturated pilor]. The gastric lesions, the gastric juice volume and the total acidity at 6, 24 and 48 hours after the treatment were examined. Ranitidine serum content was determined by HPLC. Administration of the ranitidine-dextran conjugate produces a higher inhibition of gastric lesions at 48 hours than the administration of the free drug (61.4% versus 33.9%) and a prolonged action for more 48 hours. Synthesis of a macromolecular prodrug of ranitidine and its in vitro behavior was reported in a previous paper (11). The present paper studies the performances obtained in gastro-protective action by using the new ranitidine-dextran conjugate reported (11).


Asunto(s)
Antiulcerosos/uso terapéutico , Dextranos/uso terapéutico , Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Ranitidina/uso terapéutico , Animales , Antiulcerosos/sangre , Carbacol/farmacología , Preparaciones de Acción Retardada , Dextranos/sangre , Combinación de Medicamentos , Evaluación Preclínica de Medicamentos , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/metabolismo , Antagonistas de los Receptores H2 de la Histamina/sangre , Ligadura , Píloro/cirugía , Ranitidina/sangre , Ratas , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA